EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus

According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effectiv...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autor principal: Gagik Radikovich Galstyan
Formato: article
Lenguaje:EN
RU
Publicado: Endocrinology Research Centre 2013
Materias:
Acceso en línea:https://doaj.org/article/05a818a1512f45d2a2c1afbc3ea75738
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:05a818a1512f45d2a2c1afbc3ea75738
record_format dspace
spelling oai:doaj.org-article:05a818a1512f45d2a2c1afbc3ea757382021-11-14T09:00:18ZEDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus2072-03512072-037810.14341/2072-0351-3761https://doaj.org/article/05a818a1512f45d2a2c1afbc3ea757382013-06-01T00:00:00Zhttps://www.dia-endojournals.ru/jour/article/view/3761https://doaj.org/toc/2072-0351https://doaj.org/toc/2072-0378According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effective Diabetes control with vildaGliptin and vildagliptin/mEtformin) was to assess the efficacy and safety of vildagliptin in comparison with other oral agents in routine management of patients with T2DM that has been poorly controlled by metformin monotherapy.Gagik Radikovich GalstyanEndocrinology Research Centrearticlediabetes mellitushypoglycemic agentsefficacyvildagliptineNutritional diseases. Deficiency diseasesRC620-627ENRUСахарный диабет, Vol 16, Iss 2, Pp 82-87 (2013)
institution DOAJ
collection DOAJ
language EN
RU
topic diabetes mellitus
hypoglycemic agents
efficacy
vildagliptine
Nutritional diseases. Deficiency diseases
RC620-627
spellingShingle diabetes mellitus
hypoglycemic agents
efficacy
vildagliptine
Nutritional diseases. Deficiency diseases
RC620-627
Gagik Radikovich Galstyan
EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
description According to international consensus, metformin is acknowledged as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM). However, in most cases this treatment eventually requires intensification by supplementation with other hypoglycemic medications. The aim of the EDGE study (Effective Diabetes control with vildaGliptin and vildagliptin/mEtformin) was to assess the efficacy and safety of vildagliptin in comparison with other oral agents in routine management of patients with T2DM that has been poorly controlled by metformin monotherapy.
format article
author Gagik Radikovich Galstyan
author_facet Gagik Radikovich Galstyan
author_sort Gagik Radikovich Galstyan
title EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
title_short EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
title_full EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
title_fullStr EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
title_full_unstemmed EDGE study in Russian Federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
title_sort edge study in russian federation: efficacy and safety of vildagliptine in comparison with other oral antidiabetic agents in patients with type 2 diabetes mellitus
publisher Endocrinology Research Centre
publishDate 2013
url https://doaj.org/article/05a818a1512f45d2a2c1afbc3ea75738
work_keys_str_mv AT gagikradikovichgalstyan edgestudyinrussianfederationefficacyandsafetyofvildagliptineincomparisonwithotheroralantidiabeticagentsinpatientswithtype2diabetesmellitus
_version_ 1718429569323630592